Reducing toxicity of 4–1BB costimulation: Targeting 4–1BB ligands to the tumor stroma with bi-specific aptamer conjugates

Brett Schrand, A. Berezhnoy, R. Brenneman, A. Williams, A. Levay, Eli Gilboa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Systemic administration of immune modulatory antibodies to cancer patients is associated with autoimmune pathologies. We have developed a clinically feasible and broadly applicable approach to limit immune stimulation to disseminated tumor lesions using a bi-specific agonistic 4–1BB oligonucleotide aptamer targeted to a broadly expressed stromal product (e.g., VEGF or osteopontin). The stroma-targeted aptamer conjugates engendered potent antitumor immunity against unrelated tumors and exhibited a superior therapeutic index compared to non-targeted agonistic 4–1BB antibody.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalOncoImmunology
Volume4
Issue number3
DOIs
StatePublished - 2015

Fingerprint

Ligands
Neoplasms
Osteopontin
Antibodies
Oligonucleotides
Vascular Endothelial Growth Factor A
Immunity
Pathology
Therapeutics

Keywords

  • 4–1BB
  • Autoimmune pathology
  • Cancer immunotherapy
  • Immune stimulation
  • Tumor stroma
  • Tumor targeting
  • VEGF

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Reducing toxicity of 4–1BB costimulation : Targeting 4–1BB ligands to the tumor stroma with bi-specific aptamer conjugates. / Schrand, Brett; Berezhnoy, A.; Brenneman, R.; Williams, A.; Levay, A.; Gilboa, Eli.

In: OncoImmunology, Vol. 4, No. 3, 2015, p. 1-3.

Research output: Contribution to journalArticle

@article{baf04faa8f9e43de97c9506f39ca55eb,
title = "Reducing toxicity of 4–1BB costimulation: Targeting 4–1BB ligands to the tumor stroma with bi-specific aptamer conjugates",
abstract = "Systemic administration of immune modulatory antibodies to cancer patients is associated with autoimmune pathologies. We have developed a clinically feasible and broadly applicable approach to limit immune stimulation to disseminated tumor lesions using a bi-specific agonistic 4–1BB oligonucleotide aptamer targeted to a broadly expressed stromal product (e.g., VEGF or osteopontin). The stroma-targeted aptamer conjugates engendered potent antitumor immunity against unrelated tumors and exhibited a superior therapeutic index compared to non-targeted agonistic 4–1BB antibody.",
keywords = "4–1BB, Autoimmune pathology, Cancer immunotherapy, Immune stimulation, Tumor stroma, Tumor targeting, VEGF",
author = "Brett Schrand and A. Berezhnoy and R. Brenneman and A. Williams and A. Levay and Eli Gilboa",
year = "2015",
doi = "10.4161/21624011.2014.970918",
language = "English (US)",
volume = "4",
pages = "1--3",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Reducing toxicity of 4–1BB costimulation

T2 - Targeting 4–1BB ligands to the tumor stroma with bi-specific aptamer conjugates

AU - Schrand, Brett

AU - Berezhnoy, A.

AU - Brenneman, R.

AU - Williams, A.

AU - Levay, A.

AU - Gilboa, Eli

PY - 2015

Y1 - 2015

N2 - Systemic administration of immune modulatory antibodies to cancer patients is associated with autoimmune pathologies. We have developed a clinically feasible and broadly applicable approach to limit immune stimulation to disseminated tumor lesions using a bi-specific agonistic 4–1BB oligonucleotide aptamer targeted to a broadly expressed stromal product (e.g., VEGF or osteopontin). The stroma-targeted aptamer conjugates engendered potent antitumor immunity against unrelated tumors and exhibited a superior therapeutic index compared to non-targeted agonistic 4–1BB antibody.

AB - Systemic administration of immune modulatory antibodies to cancer patients is associated with autoimmune pathologies. We have developed a clinically feasible and broadly applicable approach to limit immune stimulation to disseminated tumor lesions using a bi-specific agonistic 4–1BB oligonucleotide aptamer targeted to a broadly expressed stromal product (e.g., VEGF or osteopontin). The stroma-targeted aptamer conjugates engendered potent antitumor immunity against unrelated tumors and exhibited a superior therapeutic index compared to non-targeted agonistic 4–1BB antibody.

KW - 4–1BB

KW - Autoimmune pathology

KW - Cancer immunotherapy

KW - Immune stimulation

KW - Tumor stroma

KW - Tumor targeting

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84954515793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954515793&partnerID=8YFLogxK

U2 - 10.4161/21624011.2014.970918

DO - 10.4161/21624011.2014.970918

M3 - Article

AN - SCOPUS:84954515793

VL - 4

SP - 1

EP - 3

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 3

ER -